Laryngeal preservation in ENT oncology. Retrospective series of 246 patients managed in the Caen University Hospital and François Baclesse Cancer Care Center between 1998 and 2008

Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Jun;132(3):129-34. doi: 10.1016/j.anorl.2015.03.007. Epub 2015 Mar 30.

Abstract

Objectives: A 10-year retrospective study investigated factors for survival and laryngeal preservation in advanced laryngeal, hypopharyngeal or epilaryngeal neoplasia.

Material and method: Two hundred and forty-six patients with advanced cancer of the larynx (17.48%), hypopharynx (48.78%) or epilarynx (33.74%) undergoing primary organ-sparing treatment were included from 1998 to 2008. Treatment comprised chemotherapy followed by radiation therapy for 92.68% of patients, isolated radiation therapy for 1.6% and concomitant or sequential radiation-chemotherapy for 5.7%. General health status, history and tumor status were recorded. Factors influencing survival were analyzed by Kaplan-Meier estimator, log-rank test and Cox models.

Results: Median overall survival of the population was 2.3 years and median laryngeal preservation 0.99 years in male patients and 2 years in female patients. Survival correlated significantly with body mass index (BMI; P=0.0004), WHO performance status (P=0.0064), alcohol consumption (P=0.0004) and cessation (P<0.0001) and also T stage (P=0.0038), initial laryngeal mobility (P=0.0002) and post-chemotherapy assessment (P<0.0001). Survival with functional larynx correlated with baseline BMI at first consultation (P=0.016), baseline WHO grade (P=0.0005), laryngeal mobility (P<0.0001), T staging (P=0.0009), and T and/or N chemotherapy response to a classical organ preservation protocol (P<0.0001).

Conclusion: Over and above established criteria, the present study highlighted the importance of general health and nutritional status during treatment.

Keywords: BMI; Chemotherapy; Laryngeal cancer; Laryngeal preservation; Laryngeal surgery; Radiation therapy.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alcohol Drinking / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Body Mass Index
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / therapy*
  • Chemotherapy, Adjuvant* / methods
  • Combined Modality Therapy
  • Female
  • France
  • Humans
  • Kaplan-Meier Estimate
  • Laryngeal Neoplasms / diagnosis
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / therapy*
  • Laryngectomy*
  • Male
  • Middle Aged
  • Organ Sparing Treatments* / methods
  • Radiotherapy, Adjuvant* / methods
  • Retrospective Studies
  • Risk Factors
  • Smoking / adverse effects
  • Treatment Outcome